Verastem Inc
F:2VS
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
V
|
Verastem Inc
F:2VS
|
US |
|
Apple Inc
NASDAQ:AAPL
|
US |
|
Industrivarden AB
OTC:IDDTF
|
SE |
|
A
|
Amphenol Corp
F:XPH
|
US |
|
A
|
AstraZeneca PLC
XMUN:ZEG
|
UK |
|
L
|
Lam Research Corp
XBER:LAR
|
US |
Verastem Inc
Verastem is a biotechnology company focused on cancer drugs, especially medicines that target tumors driven by the RAS/MAPK signaling pathway. Its main work is to develop, test, and bring to market prescription therapies for hard-to-treat cancers, with a strong emphasis on ovarian cancer and other solid tumors. In simple terms, it is a drug maker, not a hospital or a research tools company. The company sells its treatments through the medical system, so its main customers are oncologists, cancer centers, hospitals, and the pharmacies and payers that support patient access. Verastem makes money mainly from sales of approved drugs, and it can also earn income from collaboration, licensing, or development agreements tied to its drug pipeline. Because it is a biotech company, a big part of its value comes from whether its clinical programs lead to approved medicines that doctors can prescribe. What makes Verastem different is its narrow focus on a specific cancer biology pathway and on combination therapies, rather than on a broad range of medicines. That gives it a specialized role in the oncology market: it tries to find patient groups that may respond better to targeted treatment and then commercialize those therapies through the standard drug distribution and reimbursement system.
Verastem is a biotechnology company focused on cancer drugs, especially medicines that target tumors driven by the RAS/MAPK signaling pathway. Its main work is to develop, test, and bring to market prescription therapies for hard-to-treat cancers, with a strong emphasis on ovarian cancer and other solid tumors. In simple terms, it is a drug maker, not a hospital or a research tools company.
The company sells its treatments through the medical system, so its main customers are oncologists, cancer centers, hospitals, and the pharmacies and payers that support patient access. Verastem makes money mainly from sales of approved drugs, and it can also earn income from collaboration, licensing, or development agreements tied to its drug pipeline. Because it is a biotech company, a big part of its value comes from whether its clinical programs lead to approved medicines that doctors can prescribe.
What makes Verastem different is its narrow focus on a specific cancer biology pathway and on combination therapies, rather than on a broad range of medicines. That gives it a specialized role in the oncology market: it tries to find patient groups that may respond better to targeted treatment and then commercialize those therapies through the standard drug distribution and reimbursement system.
Launch: Verastem reported $17.5 million of net product revenue in Q4 2025 and $30.9 million for the May–December 2025 launch period, with steady month‑to‑month growth and nearly 300 prescribers through February.
NCCN update: The recent NCCN guideline update did not expand the recommendation to include KRAS wild‑type recurrent LGSOC — management called this disappointing but said it does not change the commercial trajectory.
Access: Payer coverage remains strong across LGSOC patients regardless of KRAS status; typical fill times are 12–14 days and ~60% of commercially eligible patients use the company's co‑pay program.
Clinical pipeline: RAMP 301 Phase III enrollment is complete with topline expected mid‑2027; RAMP 205 pancreatic expansion data expected in Q2 2026; VS‑7375 (KRAS G12D inhibitor) is in dose escalation with 900 mg cleared and 1,200 mg being evaluated.
VS‑7375 development: FDA requested the Phase I/II program be split into disease‑specific Phase II registration‑directed trials for pancreatic, lung and colorectal cancers — management views this as clarifying the regulatory path.
Safety: Early U.S. VS‑7375 tolerability appears better than reported in China (lower GI events, no liver abnormalities reported to date); company is continuing dose escalation and prophylactic measures.
Finances & runway: Cash, cash equivalents and investments were $205.0 million (pro forma $234.4 million after warrant exercise); management expects cash runway into the first half of 2027 and believes the LGSOC franchise will be self‑sustaining in the second half of 2026.
